Basilea partner Asahi Kasei Therapeutics starts Japan Phase 2 pediatric Cresemba trial

By Public Technologies
  • Basilea reported partner Asahi Kasei Therapeutics started a Phase 2 pediatric Cresemba trial in Japan for deep-seated fungal infection risk.
  • No results have been presented; the study will generate future safety and pharmacokinetic data to support potential pediatric use in Japan.
  • The open-label, single-arm design targets children vulnerable to invasive fungal disease, where treatment options remain limited.
  • Cresemba is already cleared for pediatric use in the US, Canada, Europe, China; Japan currently limits it to adults.
  • Global in-market sales reached USD 782 million for April 2025–March 2026, up 27%, reinforcing the brand’s commercial momentum.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140115OMX_____CNEWS_DE_GNW1001262417_de) on September 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.